Comparison of neurotensin responses to MDL 100,907, a selective 5HT(2A) antagonist, with clozapine and haloperidol

Brain Research Bulletin

Volumn 42, Issue 3, 1997, Pages 211-219

  Hanson, Glen R ^a   Bush, Lloyd G ^a   Taylor, Vicki L ^a,b   Gibb, James W ^a   Davis, Kim ^a   Schmidt, Christopher J ^a  

^a UNIVERSITY OF UTAH   (United States)

^b Merrell Dow Research Institute   (United States)

Author keywords

Antipsychotics; Clozapine; Dopamine; Limbic; Neurotensin; Serotonin

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; CLOZAPINE; DOPAMINE; HALOPERIDOL; NEUROTENSIN; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; EXTRAPYRAMIDAL SYSTEM; IMMUNOREACTIVITY; LIMBIC SYSTEM; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PSYCHOSIS; RAT; SCHIZOPHRENIA;

ANIMALS; CAUDATE NUCLEUS; CLOZAPINE; FLUOROBENZENES; GLOBUS PALLIDUS; HALOPERIDOL; MALE; NEUROTENSIN; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN ANTAGONISTS;

EID: 0031014532     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-9230(96)00258-4     Document Type: Article

References (56)

1. Axelsson R., Nilsson A., Christensson E., Björk A. Effects of amperozide in schizophrenia. Psychopharmacol. 104:1991;287-292.
2. Baldessarini R., Frankenburg F. Drug therapy: Clozapine. N. Engl. J. Med. 324:1991;746-754.
3. Bissette G., Dauer W. T., Kilts C. D., O'Connor L., Nemeroff C. B. The effect of the stereoisomers of butaclamol on neurotensin content in discrete regions of the rat brain. Neuropsychopharmacology. 1:1988;329-335.
4. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
5. Breier A., Buchanan R. W., Kirkpatrick K. B., Davis O. R., Irish D., Summerfelt A., Carpenter W. T. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am. J. Psychiat. 151:1994;20-26.
6. Brier A. Serotonin, schizophrenia and antipsychotic drug action. Schizophrenia Res. 14:1995;187-202.
7. 3H] neurotensin binding by unilateral intrastriatal 6-hydroxydopamine injections: Evidence from a receptor autoradiographic study. Brain Res. 564:1991;37-44.
8. Carlsson M. L. The selective 5-HT2A receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse-implications for psychosis. J. Neurol. Trans. 100:1995;225-237.
9. Carlton P. L., Manowitz P. Dopamine and schizophrenia: An analysis of theory. Neurosci. Biobehav. Rev. 8:1984;137-151.
10. Castel M. N., Morino P., Frey P., Terenius L., Hökfelt T. Immunohistochemical evidence for a neurotensin striatonigral pathway in the rat brain. Neurosci. 55:1993;833-847.
11. Ceulemans D. L., Gelders Y. C., Hoppenbrouwers M. L., Reyntjens A. J., Janssen P. A. Effect of serotonin antagonism in schizophrenia: A pilot study with setoperone. Psychopharmacol. (Berl.). 85:1985;329-332.
12. Dilts R., Kalivas P. Autoradiographic localization of μ -opioid and neurotensin receptors within mesolimbic dopamine system. Brain Res. 488:1989;311-327.
13. Duinkerke S. J., Botter P. A., Jansen A. A., van Dongen P. A., van Haaften A. J., Boom A. J., van Laarhaven J. H., Busard H. L. Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind study. Brit. J. Psych. 163:1993;451-455.
14. Garver D. L., Bissette G., Widerlov E., Nemeroff C. B. CSF neurotensin concentrations in psychosis: Relationship to symptoms and drug response. Am. J. Psychiatry. 148:1991;484-488.
15. Geriach J. New antipsychotics: Classification, efficacy, and adverse effects. Schizophrenia Bull. 17:1991;289-309.
16. Glennon R. A., Dukat M. Serotonin receptor subtypes. Bloom F., Kupfer D. J. Psychopharmacology: The Fourth Generation. 1995;415-429 Raven Press, New York.
17. Goldstein M., Deutch A. Dopaminergic mechanisms in the pathogenesis of schizophrenia. FASEB J. 6:1992;2413-2421.
18. Govoni S., Hong J. S., Yang H. -Y. T., Costa E. Increase of neurotensin content elicited by neuroleptic in nucleus accumbens. J. Pharmacol. Exp. Ther. 215:1980;413-417.
19. Gygi S., Gibb J. W., Hanson G. R. Differential effects of antipsychotic and psychotomimetic drugs on neurotensin systems of discrete extrapyramidal and limbic regions. J. Pharmacol. Exp. Ther. 270:1994;192-194.
20. Haracz J. L. The dopamine hypothesis: An overview of studies with schizophrenic patients. Schizophrenia Bull. 8:1982;438-469.
21. Humphrey P., Hartig P., Hoyer D. A proposed new nomenclature for 5HT receptors. Trends in Pharmacological Sciences. 14:1993;233-236.
22. Joyce J. N., Shane A., Lexow N., Winokur A., Casanova M. F., Kleinman J. E. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacol. 8:1993;315-336.
23. Joyce J. The dopamine hypothesis of schizophrenia: Limbic interactions with serotonin and norepinephrine. Psychopharmacol. 112:1993;S16-S34.
24. Kane J. Newer antipsychotic drugs. Drugs. 46:1993;585-593.
25. Kilts C., Anderson C., Bissette G., Ely T., Nemeroff C. Differential effects of antipsychotic drugs on the neurotensin concentration of discrete rat brain nuclei. Biochem. Pharmacol. 37:1988;1547-1554.
26. Kitabgi P. Commentary, neurotensin modulates dopamine neurotransmission at several levels along brain dopaminergic pathways. Neurochem. Int. 14:1989;111-119.
27. König J. F. R., Klippel R. A. The rat brain: A Stereotaxic atlas of the forebrain and lower parts of the brain stem. 1963;Williams & Wilkins Company, Baltimore.
28. Letter A. A., Matsuda L. A., Merchant K. M., Gibb J. W., Hanson G. R. Characterization of dopaminergic influence on striatal-nigral neurotensin systems. Brain Res. 442:1987;200-203.
29. Letter A. A., Merchant K. M., Gibb J. W., Hanson G. R. Effect of methamphetamine on neurotensin concentrations in rat brain regions. J. Pharmacol. Exp. Ther. 241:1987;443-447.
30. Levant B., Nemeroff C. B. Sigma receptor "antagonist" BMY 14802 increases neurotensin concentrations in the rat nucleus accumbens and caudate. J. Pharmacol. Exp. Ther. 254:1990;330-335.
31. Lieberman J. A. Understanding the mechanism of action of atypical antipsychotic drugs. Brit. J. Psychiatry. 163:1993;7-18.
32. Lindström L. H., Widerlöv E., Bissette G., Nemeroff C. B. Reduced CSF neurotensin concentrations in drug-free schizophrenic patients. Schizophrenia Res. 1:1988;55-59.
33. Maidment N., Siddall B., Rudolph V., Erdelyi E., Evans C. Dual determination of extracellular cholecystokinin and neurotensin fragments in rat forebrain: Microdialysis combined with a sequential multiple antigen radioimmunoassay. Neurosci. 45:1991;81-93.
34. Matthysee S. W. Antipsychotic drug action: A clue to the neuropathology of schizophrenia? Fed. Proc. 32:1973;200-205.
35. Meltzer H. Y., Nash J. F. VII. Effects of antipsychotic drugs on serotonin receptors. Pharmacol. Rev. 43:1991;587-603.
36. Meltzer H. Y. The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics. J. Clinical Psychopharmacol. 15:1995;2S-3S.
37. Merchant K. M., Dobner P., Dorsa D. M. Differential effects of haloperidol and clozapine on neurotensin gene transcription in rat neostriatum. J. Neurosci. 12:1992;652-663.
38. Nemeroff C. B., Bissette G., Prange A. J., Loosen P. T. Jr, Lipton M. A. Neurotensin: Central nervous system effects of a hypothalamic peptide. Brain Res. 128:1977;485-496.
39. Nemeroff C. B. Neurotensin: Perchance an endogenous neuroleptic? Biol. Psychiatry. 15:1980;283-302.
40. Nemeroff C. B., Luttinger C., Fernandez D. E., Mailman R. B., Mason G. A., Davis S. D., Widerlov E., Frye G. D., Kilts C. D., Beaumont K., Breese G. R., Prange A. J. Jr. Interaction of neurotensin with dopamine systems: Biochemical and behavioral studies. J. Pharmacol. Exp. Ther. 225:1983;337-345.
41. Nemeroff C. B., Berger P. A., Bissette G. Peptides in schizophrenia. Meltzer H. Y. Psychopharmacology: The third generation. 1987;727-740 Raven Press, New York.
42. Nemeroff C. B. Neuropeptides and schizophrenia. Advances in neuropsychiatry and psychopharmacology. Schizophrenia research. 1:1991;77-89 Raven, Press, New York.
43. Okuma Y., Fukuda Y., Osumi Y. Neurotensin potentiates the potassium-induced release of endogenous dopamine from rat striatal slices. Eur. J. Pharmacol. 93:1983;27-33.
44. Osbahr A. J., Nemeroff C. B. III, Manberg P. J., Prange A. J. Jr. Centrally administered neurotensin: Activity in the Jolou - Courvoisier muscle relaxation test in mice. Eur. J. Pharmacol. 54:1979;299-302.
45. Palfreyman M., Schmidt C., Sorensen S., Dudley M., Kehne J., Moser P., Gittos M., Carr A. Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function. Psychopharmacol. 112:1993;S60-S67.
46. Schmidt C. J., Fadayel G. M., Sullivan C. K., Taylor V. L. 5HT2 receptors exert a state-dependent regulation of dopaminergic function: Studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine. Eur. J. Pharmacol. 223:1992;65-74.
47. Schmidt C. J., Kehne J. H., Carr A. A., Fadayel G. M., Humphreys T. M., Kettler H. J., McCloskey T. C., Padich R. A., Taylor V. L., Sorensen S. M. Contributions of serotonin neurotoxins to understanding psychiatric disorders: The role of 5HT2 receptors in schizophrenia and antipsychotic activity. Int. Clin. Psychopharmacol. 8:((Suppl. 2)):1993;25-32.
48. 2A receptor antagonist, MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat. Eur. J. Pharmacol. 273:1995;273-279.
49. 2A receptors in antipsychotic activity. Life Sciences. 56:1995;2209-2222.
50. Schotte A., Leysen J. E. Autoradiographic evidence for the localization of high affinity neurotensin binding sites on dopaminergic nerve terminals in the nigrostriatal and mesolimbic pathways in rat brain. J. Chem. Neuroanat. 2:1989;253-257.
51. Snijders R., Kramarcy N. R., Hurd R. W., Nemeroff C. B., Dunn A. J. Neurotensin induces catalepsy in mice. Neuropharmacology. 21:1982;465-468.
52. Snyder S. H. The dopamine hypothesis of schizophrenia: Focus on the dopamine receptor. Am. J. Psychiatry. 133:1976;197-202.
53. Sorensen S. M., Kehne J. H., Fadayel G. M., Humphreys T. M., Ketteler H. J., Sullivan C. K., Taylor V. L., Schmidt C. J. Characterization of the 5-HT2 receptor antagonist MDL 100,907 as a putative atypical antipsychotic: Behavioral, electrophysiological and neurochemical studies. J. Pharmacol. Exp. Ther. 266:1993;684-691.
54. Stevens J. R. An anatomy of schizophrenia? Arch. Gen. Psychiatry. 29:1973;177-189.
55. Tanganelli S., O'Connor W., Ferraro L., Bianchi C., Beani L., Ungerstedt U., Fuxe K. Facilitation of GABA release by neurotensin is associated with a reduction of dopamine release in rat nucleus accumbens. Neurosci. 60:1994;649-657.
56. Widerlov E., Lindstrom L. G., Besev G., Manberg P. J., Nemeroff C. B., Breese G. R., Kizer J. S., Prange A. J. Jr. Subnormal cerebrospinal fluid levels of neurotensin in a subgroup of schizophrenics: Normalization after neuroleptic treatment. Am. J. Psychiatry. 139:1982;1122-1126.